In ovarian cancer, the PARP inhibitor significantly upregulated PD-L1 expression through the Chk1 pathway in vitro, and treatment with anti-PD-L1 could reverse the suppression of CD8+ T cells caused by PARP inhibitor treatment. Here, CD274 is linked to ovarian carcinoma.